Mark Scalzo
Impact in
-
- Radiopharmaceutical Chemistry and Applications
- Medical Imaging Techniques and Applications
-
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
Papers in
-
- Prostate Cancer Treatment and Research 9
- Lung Cancer Treatments and Mutations 1
-
- Radiopharmaceutical Chemistry and Applications 9
- Medical Imaging Techniques and Applications 2
- Boron Compounds in Chemistry 1
- Co-authors
- Michael S. Hofman (9 shared papers)John Violet (8 shared papers)Price Jackson (7 shared papers)Rodney J. Hicks (7 shared papers)Shahneen Sandhu (8 shared papers)Scott Williams (8 shared papers)Declan G. Murphy (5 shared papers)Aravind Ravi Kumar (5 shared papers)
In The Last Decade
Mark Scalzo
10 papers receiving 1.3k citations
Hit Papers
Peers
Comparison fields: 5 of 57
- Radiology, Nuclear Medicine and Imaging 1.1k
- Pulmonary and Respiratory Medicine 1.1k
- Oncology 398
- Radiation 85
- Cancer Research 117
Countries citing papers authored by Mark Scalzo
This map shows the geographic impact of Mark Scalzo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Scalzo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Scalzo more than expected).
Fields of papers citing papers by Mark Scalzo
This network shows the impact of papers produced by Mark Scalzo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Scalzo. The network helps show where Mark Scalzo may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark Scalzo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study Hit paper breakdown → | 2018 | 815 |
| 2 | Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes Hit paper breakdown → | 2018 | 339 |
| 3 | 2019 | 84 | |
| 4 | 2020 | 37 | |
| 5 | 2022 | 34 | |
| 6 | 2017 | 7 | |
| 7 | 2019 | 7 | |
| 8 | High activity, pain reduction and low toxicity with Lutetium-177 PSMA617 theranostics in metastatic castrate-resistant prostate cancer (mCRPC): results of a phase II prospective trial | 2018 | 3 |
| 9 | 2021 | 2 | |
| 10 | 2024 | 1 |
About Mark Scalzo
Mark Scalzo is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging, Oncology, Physiology and Nutrition and Dietetics, having authored 10 papers that have together received 1.3k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (9 papers), Radiopharmaceutical Chemistry and Applications (9 papers), Cancer Immunotherapy and Biomarkers (2 papers), Medical Imaging Techniques and Applications (2 papers), Boron Compounds in Chemistry (1 paper), Biochemical Analysis and Sensing Techniques (1 paper), Lung Cancer Treatments and Mutations (1 paper) and Cancer, Lipids, and Metabolism (1 paper). The work is most often cited by research in Radiology, Nuclear Medicine and Imaging (1.1k citations), Pulmonary and Respiratory Medicine (1.1k citations), Oncology (398 citations), Radiation (85 citations) and Cancer Research (117 citations). Mark Scalzo has collaborated with scholars based in Australia, Argentina and Singapore. Frequent co-authors include Michael S. Hofman, John Violet, Price Jackson, Rodney J. Hicks, Shahneen Sandhu, Scott Williams, Declan G. Murphy, Aravind Ravi Kumar, Sue Ping Thang and Amir Iravani. Their work appears in journals such as Journal of Clinical Oncology, Journal of Nuclear Medicine, Physiology & Behavior, Annals of Oncology and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.